Pharmacological Inhibition of JNK Signalling Exerts Anti-Neoplastic Effects on SH-SY5Y Human Neuroblastoma Cells.

Zuzanna Granek, Natalia Siwecka, Kamil Saramowicz, Grzegorz Galita, Michał Golberg, Ireneusz Majsterek, Wioletta Rozpędek-Kamińska

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zuzanna GranekDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.ORCID 0000-0001-5765-1654

Natalia SiweckaDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.ORCID 0000-0002-0308-580X

Kamil SaramowiczDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.ORCID 0009-0000-0395-5986

Grzegorz GalitaDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.ORCID 0000-0002-1559-2796

Michał GolbergDepartment of Histology and Embryology, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0003-4901-6444

Ireneusz MajsterekDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.

Wioletta Rozpędek-KamińskaDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.ORCID 0000-0001-9206-1203

Funding

Medical University of Lodz 503/1-156-07/503-11-001

6 · The paper itself

Abstract

Neuroblastoma (NB) is the most prevalent paediatric extracranial solid tumour, which remains a major therapeutic challenge, especially in cases of recurrent and disseminated disease. c-Jun N-terminal kinases (JNKs) are increasingly evidenced to play a key role in NB tumourigenesis and progression through apoptosis regulation, making selective JNK inhibitors promising candidates for use in targeted anticancer drugs in NB. Our study comprehensively investigated the acute antineoplastic potential of the selective JNK inhibitor AS601245 (JNK inhibitor V) on the human

Indexed as

Antineoplastic AgentsJNK Mitogen-Activated Protein KinasesMAP Kinase Signaling SystemNeuroblastomaProtein Kinase InhibitorsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHumansMitochondriaAntineoplastic AgentsJNK Mitogen-Activated Protein KinasesProtein Kinase Inhibitorsanticancer drugapoptosisc-Jun N-terminal kinasecytotoxicityJNK inhibitormitochondrial bioenergeticsneuroblastomasmall-molecule inhibitor

Identifiers

PMID41465323

DOI10.3390/ijms262411894

PMCPMC12732662

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.